Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hormone therapy with or without abemaciclib for early ER-positive HER2-negative breast cancer
ISRCTN89539429Phase 3Active, not recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of abemaciclib, letrozole, anastrozole, exemestane and tamoxifen in breast cancer (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Time to tumour recurrence. Started Dec 2020; status: active, not recruiting.
02
Drugs
abemaciclibletrozoleanastrozoleexemestanetamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN89539429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89539429.